Science Daily - "Scientists Identify FLT3 Gene as a Valid Therapeutic Target in Acute Myeloid Leukemia"

 – April 15, 2012 /Press Release/  –– 

Through a groundbreaking new gene sequencing technology, researchers have demonstrated that the gene FLT3 is a valid therapeutic target in Acute Myeloid Leukemia, AML, one of the most common types of leukemia. The findings, published online April 15 in Nature, are a result of collaboration among scientists at the University of California, San Francisco, Pacific Biosciences and Mount Sinai School of Medicine. The discovery may help lead to the development of new drugs to treat AML. Andrew Kasarskis, PhD, Vice Chair of the Department of Genetics and Genomic Sciences at Mount Sinai School of Medicine, said, “Sequencing hundreds of single molecules of FLT3 allowed us to see drug resistance mutations at low frequency. This increased ability to see resistance will let us identify the problem of the resistance sooner in a patient's clinical course and help us take steps to address it." Learn more